Novo Nordisk's CEO took the Washington hot seat over Ozempic prices. 3 takeaways from his testimony
CEO Lars Fruergaard Jørgensen agreed today, during a Senate committee hearing, to sit down with lawmakers and pharmacy benefit managers (PBMs) to look into the possibility of cutting list prices for the company’s popular diabetes and weight-loss drugs.
Novo Nordisk CEO Faces Senate Questions Over High Prices Of Ozempic And Wegovy In US
Novo Nordisk CEO Lars Fruergaard Jorgensen testified before the Senate Health, Education, Labor and Pensions Committee hearing in
'Miracle' Weight Loss Drug Ozempic To Enter US Price Negotiations Within A Year, Novo Nordisk CEO Says Ahead Of Senate Hearing
Novo Nordisk 's NVO CEO Lars Fruergaard Jorgensen, has revealed that their diabetes medication and often hailed as a “miracle” weight loss drug, Ozempic will soon be eligible for U.S. government price negotiations, potentially within the next year.
Blame drug 'middlemen' for the high price of Ozempic and Wegovy, Novo Nordisk CEO tells Congress
CEO Lars Fruergaard Jørgensen will shift the blame for the high prices of the company’s popular weight loss treatments to drug middlemen and the ‘complex’ U.S. health care system today during a committee hearing in Congress.
Novo CEO Blames Ozempic’s High Cost on Drug Middlemen’s Tactics
Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen will use a familiar argument to defend the US prices of blockbuster drugs Ozempic and Wegovy when he appears Tuesday before a congressional committee led by Senator Bernie Sanders: It’s the middlemen.
Novo Nordisk Stock Slips as CEO Faces Senate Inquiry Into Wegovy, Ozempic Prices
Novo Nordisk CEO Lars Fruergaard Jorgensen will testify Tuesday before a Senate panel looking into the drug maker's pricing of weight-loss drugs Wegovy and Ozempic.
Sanders Grills Novo Nordisk CEO Over High Cost Of Weight Loss Drugs
The Vermont independent says he has secured pledges from the major PBMs that they would not limit coverage of Ozempic and Wegovy if the company lowers its list prices — an announcement that CEO Lars Fruergaard Jorgensen says he wasn't aware of heading into the congressional hearing.
Novo says Ozempic to be eligible for US price negotiations in less than a year
Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a year based on current criteria, the Danish drugmaker's CEO Lars Fruergaard Jorgensen said in his written testimony on Monday.
Ozempic maker's CEO grilled over price of weight loss drugs
The CEO of the company that makes Ozempic faced a Bernie Sanders-led Senate hearing on Tuesday.
Senators press Novo Nordisk CEO on why Ozempic and Wegovy cost less abroad
Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for brand-name prescriptions.
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on ...
Sanders quizes Ozempic CEO over high prices in tense hearing
What I am asking you is, if you don’t act, 40,000 people a year could die? Is this acceptable to you?” the senator asked.
FiercePharma1d
With Novo CEO on the hot seat at Senate hearing, PBMs and insurance concerns get the spotlight
When government officials and politicians scrutinize high U.S. drug prices, the role of insurers and pharmacy benefit ...
‘Greed, greed, greed’: Sanders demands Ozempic maker lower prices
While grilling Novo Nordisk’s chief executive over the price of its blockbuster diabetes and weight-loss drugs, Ozempic and ...
Bernie Sanders demands Ozempic producer to ‘stop ripping us off’ in Senate hearing
Senators grilled Novo Nordisk CEO Lars Jorgensen at a hearing on Tuesday about the cost of diabetes drug Ozempic and weight ...